SG11201810837QA - Biarylmethyl heterocycles - Google Patents

Biarylmethyl heterocycles

Info

Publication number
SG11201810837QA
SG11201810837QA SG11201810837QA SG11201810837QA SG11201810837QA SG 11201810837Q A SG11201810837Q A SG 11201810837QA SG 11201810837Q A SG11201810837Q A SG 11201810837QA SG 11201810837Q A SG11201810837Q A SG 11201810837QA SG 11201810837Q A SG11201810837Q A SG 11201810837QA
Authority
SG
Singapore
Prior art keywords
co7d
hopewell
international
montpetit
edouard
Prior art date
Application number
SG11201810837QA
Inventor
Eldon Priestley
Samuel Reznik
Edward Ruediger
James Gillard
Oz Halpern
Wen Jiang
Jeremy Richter
Rejean Ruel
Sasmita Tripathy
Wu Yang
Xiaojun Zhang
Original Assignee
Univ Montreal
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Montreal, Bristol Myers Squibb Co filed Critical Univ Montreal
Publication of SG11201810837QA publication Critical patent/SG11201810837QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 January 2018 (04.01.2018) WIPO I PCT oimitia °nolo olon Emu Imo oimIE (10) International Publication Number WO 2018/005591 Al (51) International Patent Classification: CO7D 401/14 (2006.01) CO7D 413/10 (2006.01) CO7D 405/14 (2006.01) CO7D 417/14 (2006.01) CO7D 413/14 (2006.01) CO7D 471/04 (2006.01) CO7D 233/90 (2006.01) CO7D 257/04 (2006.01) CO7D 401/10 (2006.01) CO7D 498/10 (2006.01) CO7D 235/26 (2006.01) A61K 31/437 (2006.01) C07D 403/10 (2006.01) A61P 9/00 (2006.01) C07D 403/14 (2006.01) (21) International Application Number: PCT/US2017/039646 (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: - with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) 28 June 2017 (28.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/356,215 29 June 2016 (29.06.2016) US (71) Applicants: UNIVERSITE DE MONTREAL [CA/CA]; 2900 Edouard-Montpetit Boulevard, Montreal, Quebec H3T 1J4 (CA). BRISTOL-MYERS SQUIBB COMPA- NY [US/US]; P.O. Box 4000, Route 206 and Province Line Road, Princeton, NJ 08543-4000 (US). = (72) Inventors: PRIESTLEY, Eldon, Scott; 350 Carter Road, Hopewell, NJ 08540 (US). REZNIK, Samuel, Kaye; 15 Alton Ct. Apt. 3, Brookline, MA 02446 (US). RUEDIGER, Edward, H.; 2900 Edouard-Montpetit Boulevard, Montre- al, Quebec, H3T 1J4 (CA). GILLARD, James, R.; 2900 Edouard-Montpetit Boulevard, Montreal, Quebec, H3T 1J4 (CA). HALPERN, Oz, Scott; 350 Carter Road, Hopewell, NJ 08540 (US). JIANG, Wen; 350 Carter Road, Hopewell, NJ 08540 (US). RICHTER, Jeremy; 350 Carter Road, Hopewell, NJ 08540 (US). RUEL, Rejean; 2900 Edouard- Montpetit Boulevard, Montreal, Quebec, H3T 1J4 (CA). TRIPATHY, Sasmita; 2900 Edouard-Montpetit Boule- vard, Montreal, Quebec, H3T 1J4 (CA). YANG, Wu; 350 Carter Road, Hopewell, NJ 08540 (US). ZHANG, Xiaojun; 350 Carter Road, Hopewell, NJ 08540 (US). (74) Agent: KALYANARAMAN, Palaiyur, S. et al.; Hoff- mann & Baron, LLP, 6900 Jericho Turnpike, Syosset, NY 11791 (US). O O 00 O C (54) Title: BIARYLMETHYL HETEROCYCLES (57) : The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or [3-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments. (I)
SG11201810837QA 2016-06-29 2017-06-28 Biarylmethyl heterocycles SG11201810837QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662356215P 2016-06-29 2016-06-29
PCT/US2017/039646 WO2018005591A1 (en) 2016-06-29 2017-06-28 Biarylmethyl heterocycles

Publications (1)

Publication Number Publication Date
SG11201810837QA true SG11201810837QA (en) 2018-12-28

Family

ID=59297443

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810837QA SG11201810837QA (en) 2016-06-29 2017-06-28 Biarylmethyl heterocycles

Country Status (15)

Country Link
US (2) US11407733B2 (en)
EP (1) EP3478672B1 (en)
JP (1) JP7231414B2 (en)
KR (1) KR102538999B1 (en)
CN (1) CN109715615A (en)
AR (1) AR108906A1 (en)
AU (1) AU2017289974B2 (en)
BR (1) BR112018077075A2 (en)
CA (1) CA3029630A1 (en)
EA (1) EA039493B1 (en)
IL (1) IL263499B (en)
MX (1) MX2018015247A (en)
SG (1) SG11201810837QA (en)
TW (1) TW201811759A (en)
WO (1) WO2018005591A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10611757B2 (en) * 2016-07-11 2020-04-07 Wuhan Ll Science And Technology Development Co., Ltd. Crystalline form of chemical compound, and preparation method, composition, and application thereof
SG11202001684PA (en) 2017-10-06 2020-03-30 Forma Therapeutics Inc Inhibiting ubiquitin specific peptidase 30
CN109956870A (en) 2017-12-14 2019-07-02 南京卡文迪许生物工程技术有限公司 A kind of Luo Shasi his synthetic method and its midbody compound
EP3556760A1 (en) * 2018-04-19 2019-10-23 F. Hoffmann-La Roche AG Spiro compounds
CN112312904A (en) 2018-04-16 2021-02-02 C4医药公司 Spiro compounds
WO2020072964A1 (en) 2018-10-05 2020-04-09 Forma Therapeutics, Inc. Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
CN110479182A (en) * 2019-09-10 2019-11-22 肯特催化材料股份有限公司 A kind of polyamino Gemini surface active agent and the preparation method and application thereof
WO2023006893A1 (en) * 2021-07-30 2023-02-02 Confo Therapeutics N.V. Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling
CN115321495B (en) * 2022-07-28 2023-07-21 东北石油大学 Metal nitrogen-rich compound FeN 8 Is synthesized by the method of (2)

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO811630L (en) 1980-05-29 1981-11-30 Bayer Ag IMIDAZOAZOLYLIC ACID AMOIDS, NEW INTERMEDIATE PRODUCTS FOR THEIR PREPARATION, THEIR PREPARATION AND THEIR USE AS A MEDICINE
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
EP0400835A1 (en) 1989-05-15 1990-12-05 Merck & Co. Inc. Substituted benzimidazoles as angiotensin II antagonists
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
GB8911854D0 (en) 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
US5223499A (en) 1989-05-30 1993-06-29 Merck & Co., Inc. 6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists
US5332744A (en) 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
IL94390A (en) 1989-05-30 1996-03-31 Merck & Co Inc Di-substituted imidazo fused 6-membered nitrogen-containing heterocycles and pharmaceutical compositions containing them
US5411980A (en) 1989-07-28 1995-05-02 Merck & Co., Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists
EP0415886A3 (en) 1989-08-30 1991-10-23 Ciba-Geigy Ag Aza compounds
US5140037A (en) 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists
WO1992000067A2 (en) 1990-06-22 1992-01-09 E.I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-ii receptor antagonists
CA2062558A1 (en) * 1991-03-08 1992-09-09 Prasun K. Chakravarty Heterocyclic compounds bearing acidic functional groups as angiotensin ii antagonists
US5177074A (en) 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5798364A (en) 1992-03-26 1998-08-25 Merck Patent Gesellschaft Mit Beschrankter Haftung Imidazopyridines
DE4110019C2 (en) 1991-03-27 2000-04-13 Merck Patent Gmbh Imidazopyridines, processes for their production and pharmaceutical preparations containing them
TW274551B (en) 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
US5198438A (en) * 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
EP0586513A1 (en) 1991-05-10 1994-03-16 Merck & Co. Inc. Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
WO1993001177A1 (en) 1991-07-03 1993-01-21 Merck & Co., Inc. Substituted triazolinones
AU2338992A (en) 1991-07-26 1993-03-02 G.D. Searle & Co. Carbonate-substituted imidazo(4,5-d) pyridazine compounds for treatment of cardiovascular disorders
CZ36394A3 (en) 1991-08-19 1994-07-13 Du Pont Substituted imidazilonone derivatives and pharmaceutical preparations based thereon
EP0599999A1 (en) 1991-08-19 1994-06-08 E.I. Du Pont De Nemours And Company Angiotensin ii receptor blocking imidazolinone derivatives
ES2098403T3 (en) 1991-09-10 1997-05-01 Tanabe Seiyaku Co DERIVATIVES OF IMIDAZOINDOLIZIN AND PROCEDURE FOR ITS PREPARATION.
AU644540B2 (en) 1991-09-10 1993-12-09 Tanabe Seiyaku Co., Ltd. Imidazopyridine derivatives and process for preparation thereof
WO1993019067A1 (en) 1991-09-12 1993-09-30 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine derivatives as angiotensin ii antagonists
US5256667A (en) 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
GB2263637A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted imidazo-fused 6-membered carbocycle or heterocycle as neurotensin antagonists
EP0649424B1 (en) 1992-07-10 1998-10-07 Knoll AG Dioxcyclobutene derivatives as angiotensin ii antagonists
CA2139779A1 (en) 1992-07-17 1994-02-03 Ralph A. Rivero Substituted biphenylmethylimidazopyridines
GB2272899A (en) 1992-11-30 1994-06-01 Du Pont Merck Pharma Angiotensin-11 receptor blocking cycloalkylbenzylimidazoles
JPH06312926A (en) 1993-03-04 1994-11-08 Tanabe Seiyaku Co Ltd Angiotensin ii antagonistic agent
DE4320432A1 (en) 1993-06-21 1994-12-22 Bayer Ag Substituted mono- and bipyridylmethyl derivatives
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
US5424432A (en) 1994-05-26 1995-06-13 Merck & Co., Inc. Process for the preparation of imidazolutidine
AU5982296A (en) 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination of an angi otensin ii antagonist and spironolactone
WO1996040257A1 (en) 1995-06-07 1996-12-19 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and angiotensin ii antagonist combination therapy for treatment of congestive heart failure
PT831911E (en) 1995-06-07 2002-09-30 Searle & Co SPIRONOLACTONE AND ANGIOTENSIN II ANTAGONIST THERAPEUTICS FOR THE TREATMENT OF CONGESTIVE CARDIAC INSUFFICIENCY
ES2257771T3 (en) 1996-10-28 2006-08-01 Amersham Health As CONTRAST AGENTS.
ES2200310T3 (en) 1997-01-10 2004-03-01 MERCK & CO., INC. USE OF ANTAGONISTS OF ANGIOTENSIN II LOSARTAN AND EXP-3174 IN THE TREATMENT OF SYMPTOMATIC CARDIAC INSUFFICIENCY.
WO1999043210A1 (en) 1998-02-25 1999-09-02 Merck & Co., Inc. Method for decreasing qt dispersion or inhibiting the progression of qt dispersion with an angiotensin ii receptor antagonist
GB2337701A (en) 1998-05-26 1999-12-01 United Medical And Dental Schools Of Guys St Thomas Hospitals Treatment of ischemia with an angiotensin II antagonist
YU78601A (en) 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-thienylbenzyl)-imidazoles as angiotensin-(1-7) receptor agonists, method for the production and the utilization thereof and pharmaceutical preparations containing said compounds
DE19920815A1 (en) 1999-05-05 2000-11-09 Aventis Pharma Gmbh New sulfonamido substituted (thienyl-benzyl)-imidazole derivatives are angiotensin-(1-7) receptor agonists useful in treatment of cardiovascular and endothelial disorders
GB0014861D0 (en) 2000-06-16 2000-08-09 Pharmacia & Upjohn Spa Novel telomerase inhibitors
DE10112041A1 (en) 2001-03-14 2002-09-26 Aventis Pharma Gmbh p-Thienylbenzylamides as agonists of angiotensin (1-7) receptors, processes for their preparation, their use and pharmaceutical compositions containing them
AU2002257970B2 (en) 2001-05-31 2007-08-02 Vicore Pharma Ab Tricyclic compounds useful as angiotensin II agonists
JP2003034684A (en) 2001-06-29 2003-02-07 Biofor Inc Antifungal agent of new kind
WO2003064414A1 (en) 2002-01-29 2003-08-07 Vicore Pharma Ab. Tricyclic compounds useful as angiotensin ii agonists
WO2004046137A1 (en) 2002-11-21 2004-06-03 Vicore Pharma Ab New tricyclic angiotensin ii agonists
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US20060211866A1 (en) 2005-03-21 2006-09-21 Glenmark Pharmaceuticals Limited Process for the preparation of angiotensin receptor blockers and intermediates thereof
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US20110269717A1 (en) 2006-07-17 2011-11-03 Braincells Inc. Neurogenesis by modulating angiotensin
KR20090060333A (en) 2006-09-08 2009-06-11 노파르티스 아게 N-biaryl (hetero)arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions
PL2376101T3 (en) 2008-12-29 2016-03-31 Trevena Inc Beta-arrestin effectors and compositions and methods of use thereof
US8835471B2 (en) 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
CN102816126A (en) 2011-06-07 2012-12-12 中国药科大学 Sulfamoyl-aryl-substituted triazole derivatives with cardiovascular activity, preparation method thereof, and application thereof
DE102012004589A1 (en) 2012-03-09 2013-09-12 Forschungszentrum Jülich GmbH New angiotensin II-receptor agonist, useful for treating neurodegenerative diseases, preferably Alzheimer's dementia, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis
CN104583185A (en) 2012-08-31 2015-04-29 株式会社Api Method for producing biaryl compound
CA2911376C (en) 2013-03-15 2021-03-30 University Of Southern California Phenyl(sulfonylcarbamate) derivatives and pharmaceutical compositions thereof for the treatment of angiotensin-related diseases
WO2016011420A1 (en) 2014-07-17 2016-01-21 University Of Southern California Methods, compounds, and compositions for the treatment of musculoskeletal diseases
EP2832357A1 (en) 2013-07-29 2015-02-04 Charité - Universitätsmedizin Berlin Selective AT2 receptor agonists for use in treatment of cachexia

Also Published As

Publication number Publication date
IL263499A (en) 2019-01-31
CA3029630A1 (en) 2018-01-04
US20190202808A1 (en) 2019-07-04
BR112018077075A2 (en) 2019-04-30
AU2017289974A1 (en) 2019-01-17
CN109715615A (en) 2019-05-03
US20230045357A1 (en) 2023-02-09
JP2019519586A (en) 2019-07-11
IL263499B (en) 2022-04-01
KR20190025639A (en) 2019-03-11
WO2018005591A1 (en) 2018-01-04
AR108906A1 (en) 2018-10-10
EA201990159A1 (en) 2019-07-31
TW201811759A (en) 2018-04-01
US11407733B2 (en) 2022-08-09
KR102538999B1 (en) 2023-05-31
EA039493B1 (en) 2022-02-02
MX2018015247A (en) 2019-08-12
EP3478672A1 (en) 2019-05-08
EP3478672B1 (en) 2024-04-10
AU2017289974B2 (en) 2021-08-12
JP7231414B2 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
SG11201810837QA (en) Biarylmethyl heterocycles
SG11201909018VA (en) Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
SG11201900077QA (en) 1,3-dihydroxy-phenyl derivatives useful as immunomodulators
SG11201906465YA (en) Tigit- and light-based chimeric proteins
SG11201908560SA (en) Heterocyclic compounds useful as dual atx/ca inhibitors
SG11201900619XA (en) Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201808878UA (en) Heterocyclic compounds as ret kinase inhibitors
SG11201808163WA (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201807437XA (en) Antibodies specific to human poliovirus receptor (pvr)
SG11201901937WA (en) Pyridine compound
SG11201909429VA (en) 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylprop noate derivatives and related compounds as perorally administered profrugs of beta-lactamase inhibitors for treating bacterial infections
SG11201408397SA (en) Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201408173WA (en) Pyrimidinyl tyrosine kinase inhibitors
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201908660RA (en) N-substituted indole derivatives
SG11201901850XA (en) Dopamine-b-hydroxylase inhibitors
SG11201806480UA (en) Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases